LLY Lilly(Eli) & Co

$LLY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $7.48 up 6.55% YoY • Reported revenue of $24.4B up 38.61% YoY • Lilly raised 2026 revenue guidance to $91B and updated performance margin guidance to 52.0% to 52.5%; full-year non-GAAP EPS guidance is $35.00 to $36.00.

$LLY $NVO $VKTX One last thought- Novo is cooked. They dont have anything remotely close to retatrutide or VK2735. Cagrisema had 8.5% discontinuation due to adverse events in phase 3 Reimagine 2 diabetes study with only 13.7% weight loss at 68 weeks and 1.91% A1c reduction. Just worse in every category.

$LLY Revenue: $24.4B vs. $22.61B est. ✅(+39% YoY) Adj. EPS: $7.48 vs. $6.50 est. ✅ (+7% YoY) ▫️Mounjaro rev $10.7B ↑ 65% Raises FY'26 Sales Guidance from $85B-$87B to $91B-$92B 🔥

$LLY another great example of the "First Gap = .382 level" rule, almost a pefect hit. Last week someone insulted me for it.... I did a study on it and even published it here, no1 cared 😁😂 -- That also means, the move is over 😉

$LLY $VKTX Consolidating near the highs is very bullish/only about 1% pullback. Moving averages all moving up and catching up to the price is prepping for the next leg up… if you care about the technicals. Could be wrong as low float stock but theoretically its a good setup.

$LLY $NVO $VKTX yup. One of these days the NVO BOD will figure this out also and have to act. Amazing it's taking this long for them to figure out the obvious solution!

🚨 $LLY vs $NVO — THE RETATRUTIDE REALITY CHECK Lilly’s latest Phase 3 results look impressive. But are investors seeing the full picture? 📊 Weight loss at week 80: • Retatrutide 12 mg: −20.9% • Ozempic 2 mg: −9.4% Impressive efficacy. But look closer. ⚠️ Discontinuations due to adverse events: • Retatrutide 12 mg: 7.9% • Ozempic 2 mg: 2.7% Nearly 3× higher with retatrutide! 🔬 Important limitations: • Open-label design • Lilly-sponsored trial • Headline efficacy estimand • No direct comparison with high-dose Wegovy or CagriSema The efficacy estimand does not represent outcomes regardless of treatment discontinuation. Where are the full treatment-regimen results? Investors should evaluate tolerability, treatment persistence and real-world effectiveness — not just headline weight loss. Superior efficacy does not automatically mean superior clinical or commercial value. Science first. Marketing second.

$LLY Zepbound is the most effective drug ever. This has only begun… As insurance realizes healthier people are cheaper to insure, more will be accepted in insurance plans.

$LLY Elon hyping up LLY to round out an incredible week. Can’t wait to buy a rocket car with LLY earnings.

$LLY | UBS Maintains Eli Lilly at Buy with $1,625 PT on Obesity Growth and Earnings Momentum UBS stays bullish as obesity and diabetes demand, stronger guidance, and global franchise expansion drive continued upside. Follow more analyst insights on other tickers .

$LLY Another leg up $1480 maybe over $1540 it just gonna pop on some more upgrade or any good news. Well nothing but, good news sifar.

$LLY $VKTX Amazon and google missed earnings. Money is pouring out of AI into other growth areas my opinion on LLY run up. Should be good for viking tomorrow again 🤷‍♂️

$LLY - stock bottomed for the day…expect strong rally into close and price target raises tomorrow

$LLY $NVO $OZEM if zepbound and mounjuro already winning the war on efficacy and it’s not even close. Lily is destroying novo on injectables from head to toes. If Reta came out, it will likely cannibalize meaningful lily own shares.

$LLY LLY is firing all Cylinders as opposed to $NVO. NOvo products can only compete by uping their Semaglutide strength with efficacy tradeoffs. Markets are efficient. LLY is the real deal. Bearing NOvo, Bullish LLY!

$LLY this bich is bloated to the neck, short here with everything all the way back to 500……just needs a financial weight loss to cut all that fat

$LLY love lilly..excellent company..but TECH DOMINATES. We cannot live without our devices and technology supports med research. Buy both be prudent be safe!

$LLY More upgrades for LLY BMO to 1650 from 1400 Citi to 1650 from 1600 Scotia to 1605 from 1300 MS to 1596 from 1430

$LLY CNBC and Ricks this morning. Summarized for those who missed: People using GLP1s are at 10% in US and 3% worldwide, so market is increasing 4 super hit molecules On medicare, US will save 25B in 10 years Drop out rate is low in Medicare due to affodability for $50 co-pay Drop out rate is in general low if Insurance or companies cover for most cost. Eloratintide has very very less GI issues with 19% weightloss

$LLY Lilly needs a DAMN split! Maybe it’ll start trading differently too. Trades wacko after 9:45